Monolithic Power Systems Inc vs Smith & Nephew plc — how do they compare? Monolithic Power Systems Inc trades at $1,385.25 (market cap $65.28B), while Smith & Nephew plc trades at $30.45 (market cap $12.64B). The key difference: Monolithic Power Systems Inc is far larger — about 5.2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.57%). Which is the better fit depends on your goals.
| MPWR | SNN | |
|---|---|---|
Market Cap | $65.28B | $12.64B |
Sector | Utilities | Health |
52-Week High | $1.69K | $38.70 |
52-Week Low | $711.24 | $28.73 |
Enterprise Value | $63.94B | $15.41B |
Dividend Yield | 0.6% | 2.57% |
Signals from Pluang's Aura AI — not financial advice
MPWR trades at $1,328.80, up 1.28% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a 22.98% net margin and robust cash flow, but carries high valuation multiples like a P/E of 93.92. Analyst consensus is overwhelmingly bullish with an $1,810 price target, though news includes both AI infrastructure optimism and legal investigations.
Outlook remains positive given earnings momentum and AI-driven demand, but risks include stretched valuations and ongoing legal scrutiny. The stock offers growth exposure but requires monitoring of execution and market sentiment shifts.
No Aura AI signal available yet.
Trailing returns across standard periods
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →